ABIONYX Pharma SA (FR:ABNX)
:ABNX
Top Page
ABIONYX Pharma SA
(ABNX)
Select Model
Select Model
Rating:52Neutral
Price Target:
€4.00
▲(8.11% Upside)
Action:ReiteratedDate:03/28/26
The score is held back primarily by weak financial performance—large operating losses, ongoing cash burn, and rising leverage despite still-positive equity. Technicals are a partial offset with the stock trading above major moving averages, while valuation remains constrained by continued losses and the absence of a dividend.
Positive Factors
Specialized therapeutic platform (apoA-I)
ABIONYX’s focused platform around recombinant apoA‑I is a structural strength: a defined biologic mechanism can enable targeted clinical programs, clearer IP strategy and partner interest across inflammatory, infectious and severe disease indications, supporting durable development optionality.
Negative Factors
Persistent negative cash flow
Sustained operating and free cash outflows create a structural financing need: continued negative cash generation forces recurring capital raises or debt, dilutes shareholders or increases leverage, and constrains long‑term R&D planning unless a durable revenue or cost inflection occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized therapeutic platform (apoA-I)
ABIONYX’s focused platform around recombinant apoA‑I is a structural strength: a defined biologic mechanism can enable targeted clinical programs, clearer IP strategy and partner interest across inflammatory, infectious and severe disease indications, supporting durable development optionality.
Read all positive factors
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€126.82M
Dividend YieldN/A
Average Volume (3M)284.77K
Price to Earnings (P/E)―
Beta (1Y)-0.60
Revenue Growth-10.91%
EPS Growth-25.57%
CountryFR
Employees51
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding35,511,654
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€4.66M
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, ...
How the Company Makes Money
null...
ABIONYX Pharma SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.70M | -4.93M | -4.84M | -4.01M | -7.42M |
| Net Income | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | |||||
| Total Assets | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | |||||
| Free Cash Flow | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Positive
3.70
Price Trends
3.46
Positive
3.63
Negative
3.23
Positive
Market Momentum
0.06
Negative
55.28
Neutral
50.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Positive. The current price of 3.7 is above the 20-day moving average (MA) of 3.41, above the 50-day MA of 3.46, and above the 200-day MA of 3.23, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 50.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:ABNX
ABIONYX Pharma SA
3.60
2.43
208.75%
FR:ALCOX
Nicox SA
0.42
0.19
82.02%
FR:SIGHT
GenSight Biologics SA
0.09
-0.15
-64.29%
FR:ALSEN
Sensorion SAS
0.39
0.08
27.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.